Biomolecules, 2020 Donepezil is an acetylcholinesterase inhibitor commonly used to treat mild to moderate Alzheimer’s disease. Its use has been associated with increased bone mass in humans and animals.
Faez Saleh Al-Hamed +12 more
doaj +1 more source
The effects of donepezil in Alzheimer's disease - Results from a multinational trial [PDF]
, 1999 Donepezil has been shown to be well tolerated and to improve cognition and global function in patients with mild to moderately severe Alzheimer's disease (AD).
Burns, A. +7 more
core +1 more source
Beyond Cholinesterase Inhibition. Anti-Inflammatory Role and Pharmacological Profile of Current Drug Therapy for Alzheimer's Disease [PDF]
, 2016 Inflammation is a common response of an individual against either exogenous or endogenous damage. The role of inflammation and of inflammatory cells recently emerged also in the pathogenesis of neurodegenerative disorders. Experimental evidences show how
GIUBILEI, Franco
core +1 more source
Donepezil Potentiates Nerve Growth Factor-Induced Neurite Outgrowth in PC12 Cells
Journal of Pharmacological Sciences, 2007 Donepezil is a potent and selective acetylcholinesterase inhibitor developed for the treatment of Alzheimer’s disease. To elucidate whether donepezil causes neuronal differentiation, we examined its effect on nerve growth factor (NGF)-induced neurite ...
Toru Oda +5 more
doaj +1 more source
Trials, 2017 Background Alzheimer’s disease is a progressive neurodegenerative disease. Although some of the current treatments offer some symptomatic relief, this disease cannot be cured at present.
Weina Peng +5 more
doaj +1 more source
Effect of Water Extract of Mangosteen Pericarp on Donepezil Pharmacokinetics in Mice
Molecules, 2021 The pharmacokinetic (PK) change in a drug by co-administered herbal products can alter the efficacy and toxicity. In the circumstances that herb–drug combinations have been increasingly attempted to alleviate Alzheimer’s disease (AD), the PK evaluation ...
Mingoo Bae +7 more
doaj +1 more source
Phase I and Phase II Therapies for Acute Ischemic Stroke: An Update on Currently Studied Drugs in Clinical Research. [PDF]
, 2017 Acute ischemic stroke is a devastating cause of death and disability, consequences of which depend on the time from ischemia onset to treatment, the affected brain region, and its size.
Akyol, Onat +6 more
core +3 more sources
Adherence and Tolerability of Alzheimer's Disease Medications: A Pragmatic Randomized Trial [PDF]
, 2017 BACKGROUND/OBJECTIVES: Post-marketing comparative trials describe medication use patterns in diverse, real-world populations. Our objective was to determine if differences in rates of adherence and tolerability exist among new users to ...
Boustani, Malaz A. +8 more
core +1 more source
Donepezil improves vascular function in a mouse model of Alzheimer’s disease
Pharmacology Research & Perspectives, 2021 Cardiovascular complications in Alzheimer's disease (AD) patients can occur years to decades prior to the onset of clinical symptoms of the disease. Donepezil represents the most effective drug in the treatment of AD.
Carolina Pellegrini +10 more
doaj +1 more source
Adverse Effects of Cholinesterase Inhibitors in Dementia, According to the Pharmacovigilance Databases of the United-States and Canada. [PDF]
, 2015 This survey analyzes two national pharmacovigilance databases in order to determine the major adverse reactions observed with the use of cholinesterase inhibitors in dementia.
Abagyan, Ruben +4 more
core +3 more sources